Oncology Corporate Profile
Eli Lilly is a leading innovation-driven pharmaceutical corporation that is developing a growing portfolio of pharmaceutical products. Lilly's products treat cancer, depression, schizophrenia, attention-deficit hyperactivity disorder, diabetes, osteoporosis and many other conditions.
|Alimta®||pemetrexed||ALIMTA® is a folate analog metabolic inhibitor indicated for:|
• Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer:
• Initial treatment in combination with cisplatin.
• Maintenance treatment of patients whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
• After prior chemotherapy as a single-agent.
• Mesothelioma: in combination with cisplatin.
Limitations of Use:
• ALIMTA is not indicated for the treatment of patients with squamous cell non-small cell lung cancer.
|Cyramza™||ramucirumab||CYRAMZA TM is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated for the|
•Advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single - agent after prior fluoropyrimidine - or platinum - containing chemotherapy.
•Approved in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy to treat metastatic colorectal cancer (mCRC)
|Erbitux®||cetuximab||Erbitux® is an epidermal growth factor receptor (EGFR) antagonist indicated for|
Head and Neck Cancer
• Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.
• Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with 5-FU.
• Recurrent or metastatic squamous cell carcinoma of the head and neck
progressing after platinum-based therapy.
K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer as determined by FDA-approved tests
• in combination with FOLFIRI for first-line treatment
• in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy,
• as a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.
Limitation of Use: Erbitux (cetuximab) is not indicated for treatment of K-Ras
mutation-positive colorectal cancer.
|Gemzar®||gemcitabine hydrochloride||Ovarian Cancer — Gemzar in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.|
Breast Cancer — Gemzar in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
Non-Small Cell Lung Cancer — Gemzar is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer.
Pancreatic Cancer — Gemzar is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemzar is indicated for patients previously treated with 5-FU.
|Portrazza™||necitumumab||PORTRAZZA™ is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non - small cell lung cancer.|
View additional information on commercial products here »
|Brand / Product||Class||Area of Study||Phase||Partnership|
|abemaciclib||CDK 4/6 inhibitor||Breast cancer||III|
|arzoxifene||selective estrogen receptor modulator (SERM)||Breast cancer||III|
|enzastaurin||serine/therenine kinase inhibitor||Diffuse large B-cell Lymphoma (DLBCL)||III|
|abemaciclib||CDK 4/6 inhibitor||Non Small Cell Lung Cancer (NSCLC)||III|
|Alimta? / pemetrexed (+ pembrolizumab)||antimetabolite (a folic acid antagonist)||Non Small Cell Lung Cancer (NSCLC)||III||Merck|
|Alimta? / pemetrexed||antimetabolite (a folic acid antagonist)||Non Small Cell Lung Cancer (NSCLC)||III||Almac Diagnostics|
|Alimta? / pemetrexed (+ cisplatin)||antimetabolite (a folic acid antagonist)||Recurrent or metastatic Head & Neck cancer (squamous)||III||Almac Diagnostics|
|Cyramza? / ramucirumab / IMC-1121B||anti-VEGFR-2 monoclonal antibody||1st line metastatic Colorectal cancer||III|
|Cyramza? / ramucirumab / IMC-1121B||anti-VEGFR-2 monoclonal antibody||1st line metastatic Hepatocellular carcinoma (HCC)||III|
|Cyramza? / ramucirumab / IMC-1121B||anti-VEGFR-2 monoclonal antibody||2nd line metastatic Breast cancer||III|
|Cyramza? / ramucirumab (+ paclitaxel) / IMC-1121B||anti-VEGFR-2 monoclonal antibody||Gastric cancer||III|
|Cyramza? / ramucirumab / IMC-1121B||anti-VEGFR-2 monoclonal antibody||Non Small Cell Lung Cancer (NSCLC)||III|
|Erbitux? / cetuximab||anti-EGFR monoclonal antibody||1st line metastatic Colorectal cancer||III||Bristol-Myers Squibb|
|Erbitux? / cetuximab||anti-EGFR monoclonal antibody||1st line metastatic Non Small Cell Lung Cancer (NSCLC)||III||Bristol-Myers Squibb|
|Erbitux? / cetuximab||anti-EGFR monoclonal antibody||2nd line metastatic Non Small Cell Lung Cancer (NSCLC)||III||Bristol-Myers Squibb|
|cyramza||anti-VEGFR-2 monoclonal antibody||Bladder cancer||II|
|IMC-3G3||anti-platelet derived growth factor receptor alpha (PDGFR(alpha)) monoclonal antibody (humanized)||Breast cancer||II|
|icrucumab / LY3012212||IgG1 monoclonal antibody||Breast cancer||II|
|LY2606368||CHK1 inibitor||Breast cancer||II|
|galunisertib / LY2157299||kinase inhibitor||Glioblastoma Multiforme (GBM)||II|
|galunisertib / LY2157299||kinase inhibitor||Hepatocellular carcinoma (HCC)||II|
|LY2835219||CDK inhibitor||Mantle Cell Lymphoma (MCL)||II|
|LY2603618||CHK1 inibitor||Non Small Cell Lung Cancer (NSCLC)||II|
|IMC-3G3||anti-platelet derived growth factor receptor alpha (PDGFR(alpha)) monoclonal antibody (humanized)||Ovarian cancer||II|
|IMC-3G3||anti-platelet derived growth factor receptor alpha (PDGFR(alpha)) monoclonal antibody (humanized)||Prostate cancer||II|
|LY2510924||CXCR4 peptide inhibitor||Renal cell carcinoma (RCC)||II|
|LY2510924||CXCR4 peptide inhibitor||Small Cell Lung Cancer (SCLC)||II|
|LY2940680||hedgehog/SMO antagonist||Small Cell Lung Cancer (SCLC)||II|
|LY2801653||c-Met inhibitor||Various cancer types||II|
|LY2874455||FGF receptor inhibitor||Various cancer types||II|
|LY2875358||humanized IgG4 monoclonal antibody||Various cancer types||II|
|LY2090314||GSK3 inhibitor||Various cancer types||II|
|IMC-A12||insulin-like growth factor-1 receptor (IGF-1R) inhibitor (humanized monoclonal antibody)||Various cancer types||II|
|Cyramza? / ramucirumab / IMC-1121B||anti-VEGFR-2 monoclonal antibody||1st line metastatic Melanoma||II|
|Cyramza? / ramucirumab (+ apecitabine) / IMC-1121B||anti-VEGFR-2 monoclonal antibody||2nd line metastatic Breast cancer||II|
|IMC-18F1||anti-VEGFR-1 monoclonal antibody (humanized)||Breast cancer||I|
|IMC-18F1||anti-VEGFR-1 monoclonal antibody (humanized)||Colorectal cancer||I|
|tabalumab / LY2127399 (+ bortezomib)||BAFF antibody||Gastric cancer||I||Millennium|
|LY2157299 (+ IMCgp100 )||immunotherapy||Melanoma||I||Immunocore|
|LY2801653 (+ IMCgp100)||immunotherapy||Melanoma||I||Immunocore|
|AME133v||anti-CD20 monoclonal antibody||Non-Hodgkin's Lymphoma (NHL)||I|
|gemcitabine prodrug||antimetabolite (pyrimidine analog)||Various cancer types||I|
|IMC-3C5||IgG1 monoclonal antibody (humanized)||Various cancer types||I||Circadian Technologies|
|Unnamed||anti-VEGFR-3 monoclonal antibody||Various cancer types||I|
|Unnamed||notch inhibitor||Various cancer types||I|
|Unnamed||CSF-1R monoclonal antibody||Various cancer types||I|
|Unnamed||p7056 kinase/AKT dual inhibitor||Various cancer types||I|
|Unnamed||Pan-Raf kinase inhibitor||Various cancer types||I|
|Unnamed||P13 kinase/mTOR dual inhibitor||Various cancer types||I|
|Cyramza? / ramucirumab / IMC-1121B||anti-VEGFR-2 monoclonal antibody||Gastric cancer||Approved|
|TGF-BR2||monoclonal antibody||Various cancer types||I|
|LY2228820||p38 MAP kinase inhibitor)||Ovarian cancer||II|
|Unnamed||fibroblast growth factor receptor 1 (FGFR1) antagonist||Various cancer types||Preclinical|
|Unnamed||neuropilin monoclonal antibody||Various cancer types||Preclinical|
View additional information on product candidates here »
11/7/2016 06:56 am
(Yahoo! Finance) Nov 7, 2016 - Encouraging data in BRAF wild type advanced melanoma presented in advance of initiation of phase 3 pivotal trial next year; the third pivotal phase 3 trial of cobimetinib announced this year, reflecting robust late-stage development program.
11/3/2016 11:44 am
(Managed Healthcare Executive) Nov 3, 2016 - Oncology therapeutic and supportive care agents in the development pipeline promise to be more effective, more therapeutically targeted, more personalized—and far more costly, according to industry experts.
11/3/2016 11:33 am
(Doctors Lounge/HealthDay News) Nov 2, 2016 - The American Society of Clinical Oncology Clinical Practice Guideline on the integration of palliative care into standard oncology care has been updated. The update was published online Oct. 28 in the Journal of Clinical Oncology.
11/3/2016 06:53 am
(Reuters Health) Nov 2, 2016 – For patients with advanced cancer, palliative care should start early and be an integral part of treatment, not just something added on near the end of life, according to a new practice guideline from the American Society for Clinical Oncology (ASCO).
11/2/2016 11:36 am
(CNBC) Nov 1, 2016 - Two doctors clashed Tuesday afternoon over their stances on California's Proposition 61, a referendum that would require state agencies to get the same discount on drugs as the Department of Veteran Affairs.
11/2/2016 11:29 am
(ACCC) Nov 2, 2016 - Effective delivery of patient-centered care is essential to meet the Institute for Healthcare Improvement (IHI) Triple Aim – improved patient experience, improved outcomes, and reduced costs. As the U.S. healthcare system shifts from volume to value-based reimbursement, many new payment models incorporate patient satisfaction and/or patient experience measures when determining overall compensation.
10/31/2016 10:38 am
(ASCO in Action) Oct 27, 2016 - ASCO’s policy brief outlining the Food and Drug Administration’s (FDA) regulation of electronic cigarettes (e-cigarettes) and other Electronic Nicotine Delivery Systems (ENDS) was published in the Journal of Oncology Practice.
10/28/2016 12:19 pm
(Yahoo! Finance) Oct 27, 2016 - Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces that the National Comprehensive Cancer Network (NCCN) revised their clinical practice guidelines recommending the use of highly sensitive diagnostic tools, including NGS, to assess the presence of measurable residual disease (MRD) in Multiple Myeloma.
10/27/2016 11:45 am
(Reuters) Oct 27, 2016 - Bristol-Myers Squibb Co, whose shares have plunged since its new Opdivo immunotherapy failed an important lung-cancer trial last summer, sharply raised its 2016 profit forecast after surprisingly strong quarterly sales of other leading medicines.
10/21/2016 12:16 pm
(Myriad) Oct 21, 2016 - Myriad Genetics, Inc., a global leader in personalized medicine, and ION Solutions, a part of AmerisourceBergen, and the largest physician services organization specializing in the support of community oncology, announced today that they have entered into a relationship to deliver quality hereditary cancer test results and services to ION member practices.
10/21/2016 07:04 am
(Merck) Oct 21, 2016 - Merck, known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).
10/17/2016 11:11 am
(WhiteHouse.gov/Office of the Vice President) Oct 17, 2016 - Today in the Oval Office, Vice President Joe Biden delivered the Cancer Moonshot report to the President and the American public.
10/14/2016 11:34 am
(HHS.gov) Oct 14, 2016 - Today, the U.S. Department of Health and Human Services’ (HHS) Office of the National Coordinator for Health Information Technology (ONC) issued a final rule that emphasizes the importance of protecting public health and safety while also strengthening transparency and accountability in the ONC Health IT Certification Program (“Program”).
10/13/2016 11:07 am
(Medscape Medical News) Oct 12, 2016 - A new global guideline on screening for cervical cancer, which provides evidence-based recommendations for screening, follow-up, and treatment for high-risk lesions, has been released by the American Society of Clinical Oncology (ASCO).
10/12/2016 11:09 am
(Sirtex) Oct 11, 2016 - Sirtex Medical Limited announced today that the European Society of Medical Oncology (ESMO) has indicated the use of SIRT using yttrium-90 (Y-90) microspheres as an option for the treatment of intrahepatic cholangiocarcinoma (iCCA), a form of primary liver cancer that starts in the bile duct, the branching network of thin tubes that deliver fat-digesting bile from the liver to the small intestine.
10/11/2016 01:06 pm
(Yahoo! Finance) Oct 11, 2016 - CA-327, a PD-L1/TIM3 dual antagonist designed and optimized by Aurigene, licensed as the 2nd oral small molecule immuno-oncology development candidate under the Curis Aurigene collaboration.
10/10/2016 09:49 am
(Merck) Oct 8, 2016 - Results from interim analysis of phase 2 KEYNOTE-052 study to be presented at ESMO 2016 Congress and highlighted in ESMO press program; first presentation of data investigating KEYTRUDA in the front line treatment of bladder cancer.
10/10/2016 09:46 am
(Reuters) Oct 10, 2016 - Exelixis's drug Cabometyx outperformed Pfizer's Sutent in a clinical study for the treatment of metastatic kidney cancer, suggesting it has the potential to become a first-line treatment, researchers said on Monday.
10/7/2016 11:06 am
(UT Southwestern Medical Center) Oct 6, 2016 - Controversy over prostate cancer screening guidelines that discourage use of PSA tests did not significantly reduce use of the test, a five-year review of more than 275,000 visits at UT Southwestern Medical Center showed.
10/7/2016 11:00 am
(Yahoo! Finance) Oct 7, 2016 - Seattle Genetics, Inc. and Agensys, an affiliate of Astellas, today presented updated clinical data for enfortumab vedotin (ASG-22ME) and ASG-15ME at the European Society for Medical Oncology (ESMO) Congress being held October 7-11, 2016 in Copenhagen, Denmark.
10/7/2016 10:59 am
(Yahoo! Finance) Oct 7, 2016 - Exelixis, Inc. today announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors.
10/7/2016 10:58 am
(Yahoo! Finance) Oct 7, 2016 - Exelixis, Inc. today announced that its collaborator Genentech, a member of the Roche Group, will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of the triple combination of cobimetinib, vemurafenib, and atezolizumab in patients with previously untreated BRAF V600 mutation-positive advanced melanoma.
10/5/2016 11:08 am
(PharmaMar) Oct 5, 2016 - Results of an oral presentation will highlight the Phase II clinical trial results with lurbinectedin in patients with BRCA 1/2 metastatic breast cancer; a prospective randomized phase III comparing trabectedin versus the best supportive care in patients with pretreated advanced soft tissue sarcoma (T- SAR trial) will be presented in an oral session by the French Sarcoma Group.
9/30/2016 11:44 am
(AJMC) Sept 29, 2016 - Untreated human papillomavirus (HPV) infection has been identified as a leading cause of developing cervical intraepithelial neoplasia (CIN), which can lead to invasive cervical cancer. While several studies have documented the success of HPV vaccination in preventing the viral infection and development of low-grade and high-grade CIN, the impact of subsequent reduced screening rates have not been examined.
9/30/2016 11:35 am
(UCSF) Sept 29, 2016 - UC San Francisco scientists have engineered human immune cells that can precisely locate diseased cells anywhere in the body and execute a wide range of customizable responses, including the delivery of drugs or other therapeutic payloads directly to tumors or other unhealthy tissues.
7/10/2012 01:02 pm
7/9/2012 09:05 pm
7/9/2012 01:00 pm
7/6/2012 11:00 pm
[Business Wire] - Eli Lilly and Company and Bristol-Myers Squibb Company today announced that ERBITUXÂ® in combination with the chemotherapy regimen FOLFIRI has been granted full approval by the U.S.
7/6/2012 10:00 pm
7/6/2012 09:00 pm
7/6/2012 08:01 pm
7/6/2012 06:01 pm
7/6/2012 04:03 pm
7/6/2012 02:00 pm
7/6/2012 12:02 pm
7/6/2012 12:00 pm
[PR Newswire] - INDIANAPOLIS, July 6, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has met the United States Food and Drug Administration (FDA) requirements for pediatric exclusivity ...
7/6/2012 11:04 am
7/5/2012 06:05 pm
7/5/2012 04:03 pm
7/3/2012 06:02 pm
7/3/2012 06:01 pm
7/3/2012 04:05 pm
[at Bloomberg] - Commerce Department Keeps Icann as Web's Address Manager
7/3/2012 03:05 pm
7/3/2012 12:00 pm
7/3/2012 06:00 am
7/3/2012 04:04 am
7/3/2012 02:05 am